Premium
Bortezomib use in a pediatric cardiac transplant center
Author(s) -
Zinn Matthew D.,
L'Ecuyer Thomas J.,
Fagoaga Omar R.,
Aggarwal Sanjeev
Publication year - 2014
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.12300
Subject(s) - medicine , bortezomib , regimen , retrospective cohort study , adverse effect , sepsis , single center , surgery , multiple myeloma
Data are limited on the efficacy and safety of bortezomib for the treatment of AMR following OHT for pediatric acquired or CHD . Retrospective chart review identified patients who received bortezomib for acute (n = 3, within two wk of diagnosis) and chronic (n = 1, three months after diagnosis) AMR or as part of a desensitization regimen (n = 1). Bortezomib was associated with a 3–66% reduction in class I DSA and a 7–82% reduction in class II DSA . Two of the three acute AMR cases resolved by the first follow‐up biopsy. Two patients with AMR resolution are currently well. One patient developed a second episode of AMR , which was unresponsive to bortezomib therapy and required retransplantation for progressive coronary allograft vasculopathy. One patient died shortly after the third cycle from multi‐organ failure. The desensitization patient showed transient HLA reduction with two cycles, but died five months after transplant from sepsis. Complications included infection (3/5), peripheral neuropathy (2/5), AKI (2/5), and thrombocytopenia (3/5). Adverse events appear more common in critically ill patients. Bortezomib therapy resulted in variable DSA reduction and AMR resolution in AMR in OHT secondary to pediatric acquired or CHD .